Document Detail


Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs.
MedLine Citation:
PMID:  16120489     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Until more efficacious antiepileptic drugs (AEDs) that can tackle the challenge of drug-refractory epilepsy are developed, the best way to minimize inadequate seizure control is to exploit at best available treatments. There are however, discrepancies between commonly held opinions on several aspects of drug therapy, and the body of scientific evidence which exists to support them. This article highlights a few examples, discussing evidence that, contrary to common belief, (i) a significant proportion of patients with newly diagnosed epilepsy respond to concentrations of AEDs below the "therapeutic range" quoted in the literature; (ii) only a small group of patients unresponsive to low to moderate AED dosages become seizure-free after increasing dosage up to the limit of tolerability; (iii) knowledge of mechanisms of AED action can aid in the rational use of AEDs in the clinic; (iv) monitoring serum levels of new generation AEDs can be usefully exploited to improve management, and (v) at least in a subgroup of patients, successful epilepsy surgery cannot be regarded as curative, because seizure control may be dependent upon continuation of AED therapy. It is hoped that increased awareness of these issues could eventually contribute not only to improved clinical outcome, but also to high quality studies in many areas where gaps in knowledge prevent application of truly evidence-based management.
Authors:
Emilio Perucca
Related Documents :
23990119 - Comparative evaluation of porous versus nonporous mucoadhesive films as buccal delivery...
18279749 - Choosing the correct antiepileptic drugs: from animal studies to the clinic.
17608299 - Reinvestigation and reduction of polytherapy in children with chronic seizures.
11479399 - Gabapentin withdrawal syndrome.
23846839 - In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvasta...
24099029 - How to avoid being surprised by hepatotoxicity at the final stages of drug development ...
10935909 - Blastocystis hominis: neutral red supravital staining and its application to in vitro d...
20868429 - Intravenous lacosamide for treatment of status epilepticus.
20584229 - Drug and dietary interactions of the new and emerging oral anticoagulants.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Epileptic disorders : international epilepsy journal with videotape     Volume:  7 Suppl 1     ISSN:  1294-9361     ISO Abbreviation:  Epileptic Disord     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-25     Completed Date:  2007-05-17     Revised Date:  2008-09-16    
Medline Journal Info:
Nlm Unique ID:  100891853     Medline TA:  Epileptic Disord     Country:  France    
Other Details:
Languages:  eng     Pagination:  S14-21     Citation Subset:  IM    
Affiliation:
Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Laboratories for Diagnostics and Applied Biological Research, Institute of Neurology, IRCCS C. Mondino Foundation, Pavia, Italy. perucca@unipv.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticonvulsants / administration & dosage*,  pharmacology*
Dose-Response Relationship, Drug
Drug Resistance
Epilepsy / drug therapy*
Humans
Chemical
Reg. No./Substance:
0/Anticonvulsants
Comments/Corrections
Erratum In:
Epileptic Disord. 2008 Jun;10(2):191

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Can we predict refractory epilepsy at the time of diagnosis?
Next Document:  VNS Therapy versus the latest antiepileptic drug.